UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|||
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On November 9, 2023, Treace Medical Concepts, Inc. issued a press release regarding its financial results for the quarter ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
This information is intended to be furnished under Item 2.02 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit No. |
|
Description |
99.1 |
|
Press Release of Treace Medical Concepts, Inc. issued on November 9, 2023 |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
TREACE MEDICAL CONCEPTS, INC. |
||
|
|
|
|
|||
Date: November 9, 2023 |
|
|
|
By: |
|
/s/ Mark L. Hair |
|
|
|
|
|
|
Mark L. Hair |
|
|
|
|
|
|
Chief Financial Officer |
Exhibit 99.1
Treace Medical Concepts Reports Third Quarter 2023 Financial Results
PONTE VEDRA, Fla. – November 9, 2023 – Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction® Procedure, today reported financial results for the third quarter ended September 30, 2023.
Recent Highlights:
“We’re pleased to report substantial gains in our key performance metrics during the third quarter, including 36% year-to-date revenue growth and a significant increase in our surgeon base, which now totals 2,691, a 21% increase over the prior year,” said John T. Treace, CEO, Founder and Board Member of Treace. “We also achieved a record blended average selling price of $6,311, driven by the early impact of our new technologies, and we are particularly excited about the opportunity for our SpeedPlate™ fixation platform.”
Mr. Treace stated, “Our updated guidance reflects our year-to-date surgeon count, which was impacted by prioritized travel and vacations for our patient demographic that started in the second quarter and continued through most of the third quarter. We also made the strategic decision to further refine our SpeedPlate™ platform, extending our timeline to achieve full commercial supply until the first quarter of 2024. This decision has enabled us to make our Gen 2 SpeedPlate™ technology more broadly applicable across a greater range of clinical applications, which we believe will expand our footprint in the foot and ankle market.”
Mr. Treace continued, “With accelerating additions to our surgeon base, increasing productivity of our direct sales channel and several new technologies that are already starting to make a positive impact on customer demand, I’m confident that we have the right strategy in place to outpace our competitors, drive continued market penetration and deliver strong growth for the remainder of this year and beyond.”
1
Third Quarter 2023 Financial Results
Revenue for the second quarter of 2023 was $40.8 million, representing an increase of 23% compared to $33.1 million in the third quarter of 2022. The increase was driven by an increased number of Lapiplasty® procedure kits sold as a result of an expanded surgeon customer base, increased utilization and increased blended average selling prices due to increased adoption of the Company’s newer technologies and expanding portfolio of complementary products.
Gross profit for the third quarter of 2023 was $32.8 million, representing an increase of 21% compared to a gross profit of $27.0 million in the third quarter of 2022. Gross margin totaled 80.4% in the third quarter of 2023, compared to 81.6% in third quarter of 2022, primarily due to changes in product mix, an increase in inventory provisions, and an increase in overhead costs due to headcount to support the growing business, partially offset by lower royalty rates.
Total operating expenses were $50.6 million in the third quarter of 2023, compared to total operating expenses of $38.3 million in the third quarter of 2022. Increased operating expenses in the third quarter of 2023 reflect strategic investments in its expanding direct sales channel, investments in product innovation, increased capacity requirements, as well as support for other commercial initiatives.
Third quarter net loss attributable to common stockholders was ($17.5) million, or ($0.28) per share, compared to ($12.1) million, or ($0.22) per share, for the same period of 2022. Third quarter adjusted net loss was ($17.5) million, or ($0.28) per share, compared to ($12.1) million, or ($0.22) per share for the same period of 2022. Adjusted EBITDA was a loss of ($9.2) million in the third quarter of 2023 compared to a loss of ($8.6) million for the same period in 2022. See below for additional information and a reconciliation of non-GAAP financial information.
Cash, cash equivalents, marketable securities and investment receivable totaled $128.2 million as of September 30, 2023. The Company believes it has sufficient balance sheet strength and flexibility to continue aggressively executing on its strategic investments and growth initiatives.
Financial Outlook
Treace is updating its full-year 2023 revenue guidance to $182 million to $186 million, which represents approximately 28% to 31% growth over the Company’s 2022 revenue. This compares to the prior full-year 2023 revenue guidance of $191 million to $197 million.
The Company expects positive adjusted EBITDA in the fourth quarter of 2023 and continues to expect to show modest improvement in adjusted EBITDA for full-year 2023 compared to 2022.
An investor presentation for the Company’s third quarter 2023 financial results is available in the "Investors" section of Treace's website at investors.treace.com.
Webcast and Conference Call Details
Treace will host a conference call today, November 9, 2023, at 4:30 p.m. ET to discuss its third quarter 2023 financial results. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. The live webcast of the conference call will be available on the Investor Relations section of the Company’s website at https://investors.treace.com/. The webcast will be archived on the website following the completion of the call.
Use of Non-GAAP Financial Measures
To supplement the financial results presented in accordance with GAAP, this earnings release presents Adjusted EBITDA, which the Company defines as net loss before depreciation and amortization expense, interest income, interest expense, taxes, share-based compensation expense, acquisition-related costs
2
and debt extinguishment loss. As of March 31, 2023, in its calculation of Adjusted EBITDA, the Company began subtracting interest income from net loss as interest income is expected to be significant for the full-year 2023. Prior period results for Adjusted EBITDA have been updated to be consistent with the updated presentation as described above. This earning release also presents net loss attributable to common stockholders excluding the debt extinguishment loss on an aggregate and per share basis (“Adjusted Net Loss”). Non-GAAP financial measures such as Adjusted EBITDA and Adjusted Net Loss are presented in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Management uses these non-GAAP financial measures to evaluate the Company’s operating performance and trends, as well as for making planning decisions. The Company believes that Adjusted EBITDA and Adjusted Net Loss helps to identify underlying trends in the Company’s business that may otherwise be masked by the effect of the income and expenses and other items that it excludes in its calculation of Adjusted EBITDA and Adjusted Net Loss. Accordingly, the Company believes these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating the Company’s operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by the Company’s management in their financial and operational decision-making. The Company also presents these non-GAAP financial measures because it believes investors, analysts and rating agencies consider them to be a useful metrics in measuring the Company’s performance against other companies and its ability to meet its debt service obligations.
There are limitations related to the use of non-GAAP financial measures such as Adjusted EBITDA and Adjusted Net Loss because they are not prepared in accordance with GAAP, may exclude significant income and expenses required by GAAP to be recognized in the Company’s financial statements, and may not be comparable to non-GAAP financial measures used by other companies. The Company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented below.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements, including, but not limited to the Company’s expectations about the opportunity for its SpeedPlate™ fixation platform, including its expansion of the Company’s footprint in the foot and ankle market and the timeline to achieve full commercial supply of that product; the Company’s confidence that it has the right strategy in place to outpace its competitors, drive continued market penetration and deliver strong growth for the remainder of 2023 and beyond; the Company’s belief that it has sufficient balance sheet strength and flexibility to continue aggressively executing on its strategic investments and growth initiatives; the Company’s revenue guidance and revenue growth rates for full-year 2023; and the Company’s expectation of positive adjusted EBITDA in the fourth quarter of 2023 and modest improvement in adjusted EBITDA for full-year 2023 compared to 2022. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results or other events to differ materially from those contemplated in this press release can be found in the Risk Factors section of Treace’s public filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2022, and any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of their date and, except to the extent required by law, the Company undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.
3
The Company’s results for the quarter ended September 30, 2023 are not necessarily indicative of its operating results for any future periods.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty®3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace expanded its offering with the Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients, and the Hammertoe PEEK Fixation System, designed to address hammertoe, claw toe and mallet toe deformities. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, Twitter, Facebook, and Instagram.
Contacts:
Treace Medical Concepts, Inc.
Julie Dewey, IRC
Chief Communications & Investor Relations Officer
jddewey@treace.com | 209-613-6945
4
Treace Medical Concepts, Inc.
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Revenue |
|
$ |
40,758 |
|
|
$ |
33,055 |
|
|
$ |
124,906 |
|
|
$ |
92,069 |
|
Cost of goods sold |
|
|
7,998 |
|
|
|
6,090 |
|
|
|
23,712 |
|
|
|
16,511 |
|
Gross profit |
|
|
32,760 |
|
|
|
26,965 |
|
|
|
101,194 |
|
|
|
75,558 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Sales and marketing |
|
|
33,542 |
|
|
|
25,568 |
|
|
|
100,970 |
|
|
|
74,477 |
|
Research and development |
|
|
4,350 |
|
|
|
3,799 |
|
|
|
11,288 |
|
|
|
9,835 |
|
General and administrative |
|
|
12,686 |
|
|
|
8,916 |
|
|
|
33,582 |
|
|
|
22,593 |
|
Total operating expenses |
|
|
50,578 |
|
|
|
38,283 |
|
|
|
145,840 |
|
|
|
106,905 |
|
Loss from operations |
|
|
(17,818 |
) |
|
|
(11,318 |
) |
|
|
(44,646 |
) |
|
|
(31,347 |
) |
Interest income |
|
|
1,570 |
|
|
|
420 |
|
|
|
5,017 |
|
|
|
560 |
|
Interest expense |
|
|
(1,296 |
) |
|
|
(1,190 |
) |
|
|
(3,863 |
) |
|
|
(3,087 |
) |
Debt extinguishment loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(4,483 |
) |
Other income, net |
|
|
23 |
|
|
|
(45 |
) |
|
|
246 |
|
|
|
(46 |
) |
Other non-operating income (expense), net |
|
|
297 |
|
|
|
(815 |
) |
|
|
1,400 |
|
|
|
(7,056 |
) |
Net loss |
|
$ |
(17,521 |
) |
|
$ |
(12,133 |
) |
|
$ |
(43,246 |
) |
|
$ |
(38,403 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Unrealized gain (loss) on marketable securities |
|
$ |
71 |
|
|
$ |
— |
|
|
$ |
(121 |
) |
|
$ |
— |
|
Comprehensive loss |
|
$ |
(17,450 |
) |
|
$ |
(12,133 |
) |
|
$ |
(43,367 |
) |
|
$ |
(38,403 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.28 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.71 |
) |
|
$ |
(0.70 |
) |
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted |
|
|
61,562,494 |
|
|
|
55,429,211 |
|
|
|
60,566,655 |
|
|
|
55,190,587 |
|
Note: A change in presentation has been made within the Statement of Operations and Comprehensive Loss for the three months and nine months ended September 30, 2022, reclassifying $0.5 million and $1.3 million of surgical instrument expense from cost of goods sold to sales and marketing expense to conform with the current year’s presentation. Please refer to supplemental materials related to quarterly 2022 results available on our investor relations website.
5
Treace Medical Concepts, Inc.
Balance Sheets
(in thousands, except share and per share amounts)
(unaudited)
|
|
September 30, |
|
|
December 31, |
|
||
|
|
2023 |
|
|
2022 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
7,278 |
|
|
$ |
19,473 |
|
Marketable securities, short-term |
|
|
114,885 |
|
|
|
61,779 |
|
Accounts receivable, net of allowance for doubtful accounts of $639 and $735 as of September 30, 2023 and December 31, 2022, respectively |
|
|
24,996 |
|
|
|
29,196 |
|
Inventories |
|
|
29,312 |
|
|
|
19,330 |
|
Prepaid expenses and other current assets |
|
|
10,671 |
|
|
|
3,624 |
|
Total current assets |
|
|
187,142 |
|
|
|
133,402 |
|
Property and equipment, net |
|
|
21,536 |
|
|
|
15,338 |
|
Intangible assets, net of accumulated amortization of $238 and $0 as of September 30, 2023 and December 31, 2022, respectively |
|
|
9,262 |
|
|
|
— |
|
Goodwill |
|
|
12,815 |
|
|
|
— |
|
Operating lease right-of-use assets |
|
|
9,459 |
|
|
|
10,138 |
|
Other non-current assets |
|
|
146 |
|
|
|
146 |
|
Total assets |
|
$ |
240,360 |
|
|
$ |
159,024 |
|
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
8,680 |
|
|
$ |
8,668 |
|
Accrued liabilities |
|
|
8,936 |
|
|
|
6,216 |
|
Accrued commissions |
|
|
5,278 |
|
|
|
7,356 |
|
Accrued compensation |
|
|
5,070 |
|
|
|
7,666 |
|
Other liabilities |
|
|
5,190 |
|
|
|
339 |
|
Total current liabilities |
|
|
33,154 |
|
|
|
30,245 |
|
Long-term debt, net of discount of $1,066 and $1,289 as of September 30, 2023 and December 31, 2022, respectively |
|
|
52,934 |
|
|
|
52,711 |
|
Operating lease liabilities, net of current portion |
|
|
16,375 |
|
|
|
15,539 |
|
Other long-term liabilities |
|
|
37 |
|
|
|
— |
|
Total liabilities |
|
|
102,500 |
|
|
|
98,495 |
|
Commitments and contingencies (Note 8) |
|
|
|
|
|
|
||
Stockholders’ equity |
|
|
|
|
|
|
||
Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 0 shares issued and outstanding as of September 30, 2023 and December 31, 2022 |
|
|
— |
|
|
|
— |
|
Common stock, $0.001 par value, 300,000,000 shares authorized; 61,606,926 issued and outstanding as of September 30, 2023; 300,000,000 shares authorized; 55,628,208 issued and outstanding as of December 31, 2022 |
|
|
62 |
|
|
55 |
|
|
Additional paid-in capital |
|
|
265,912 |
|
|
|
145,221 |
|
Accumulated deficit |
|
|
(127,966 |
) |
|
|
(84,720 |
) |
Accumulated other comprehensive (loss) income |
|
|
(148 |
) |
|
|
(27 |
) |
Total stockholders’ equity |
|
|
137,860 |
|
|
|
60,529 |
|
Total liabilities and stockholders’ equity |
|
$ |
240,360 |
|
|
$ |
159,024 |
|
6
Treace Medical Concepts, Inc.
Statements of Cash Flows
(in thousands)
(unaudited)
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Cash flows from operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(43,246 |
) |
|
$ |
(38,403 |
) |
Adjustments to reconcile net loss to net cash used in operating |
|
|
|
|
|
|
||
Depreciation and amortization expense |
|
|
3,583 |
|
|
|
1,216 |
|
(Recovery) provision for allowance for doubtful accounts |
|
|
79 |
|
|
|
(38 |
) |
Share-based compensation expense |
|
|
11,480 |
|
|
|
5,641 |
|
Non-cash lease expense |
|
|
1,868 |
|
|
|
2,010 |
|
Amortization of debt issuance costs |
|
|
223 |
|
|
|
169 |
|
Recovery of inventory obsolescence |
|
|
— |
|
|
|
(206 |
) |
Gain on fair value adjustment to derivative liability |
|
|
— |
|
|
|
(173 |
) |
Debt extinguishment loss |
|
|
— |
|
|
|
4,483 |
|
Accretion (amortization) of discount |
|
|
(1,031 |
) |
|
|
— |
|
Other, net |
|
|
164 |
|
|
|
25 |
|
Net changes in operating assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
||
Accounts Receivable |
|
|
4,121 |
|
|
|
58 |
|
Inventory |
|
|
(9,915 |
) |
|
|
(6,027 |
) |
Prepaid expenses and other assets |
|
|
(1,028 |
) |
|
|
(1,058 |
) |
Other non-current assets |
|
|
— |
|
|
|
(146 |
) |
Other liabilities |
|
|
497 |
|
|
|
3,112 |
|
Accounts payable |
|
|
12 |
|
|
|
3,825 |
|
Accrued liabilities |
|
|
(1,954 |
) |
|
|
222 |
|
Other, net |
|
|
40 |
|
|
|
— |
|
Net cash used in operating activities |
|
|
(35,107 |
) |
|
|
(25,290 |
) |
|
|
|
|
|
|
|
||
Cash flows from investing activities |
|
|
|
|
|
|
||
Purchases of available-for-sale marketable securities |
|
|
(140,075 |
) |
|
|
— |
|
Sales and maturities of available-for-sale marketable securities |
|
|
82,979 |
|
|
|
— |
|
Purchases of property and equipment |
|
|
(9,210 |
) |
|
|
(12,506 |
) |
Acquisition, net of cash acquired |
|
|
(20,000 |
) |
|
|
— |
|
Net cash used in investing activities |
|
|
(86,306 |
) |
|
|
(12,506 |
) |
|
|
|
|
|
|
|
||
Cash flows from financing activities |
|
|
|
|
|
|
||
Proceeds from interest bearing term debt |
|
|
— |
|
|
|
49,651 |
|
Proceeds from interest bearing revolving debt |
|
|
— |
|
|
|
3,850 |
|
Debt issuance costs |
|
|
— |
|
|
|
(989 |
) |
Repayment of term loan |
|
|
— |
|
|
|
(33,893 |
) |
Proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of $7.5 million |
|
|
107,527 |
|
|
|
— |
|
Proceeds from exercise of employee stock options |
|
|
1,691 |
|
|
|
1,890 |
|
Net cash provided by financing activities |
|
|
109,218 |
|
|
|
20,509 |
|
Net decrease in cash and cash equivalents |
|
|
(12,195 |
) |
|
|
(17,287 |
) |
Cash and cash equivalents at beginning of period |
|
|
19,473 |
|
|
|
105,833 |
|
Cash and cash equivalents at end of period |
|
$ |
7,278 |
|
|
$ |
88,546 |
|
|
|
|
|
|
|
|
||
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Cash paid for interest |
|
$ |
3,863 |
|
|
$ |
3,087 |
|
Operating lease right-of-use assets obtained in exchange for new lease liabilities |
|
$ |
— |
|
|
$ |
15,300 |
|
Operating lease right-of-use asset and lease liability adjustment due to lease incentive |
|
$ |
(22 |
) |
|
$ |
— |
|
Noncash investing activities: |
|
|
|
|
|
|
||
Unrealized losses on marketable securities |
|
$ |
121 |
|
|
$ |
— |
|
Unsettled marketable security purchase and payable to broker |
|
$ |
(1,100 |
) |
|
$ |
— |
|
Unsettled matured marketable security and receivable from broker |
|
$ |
6,000 |
|
|
$ |
— |
|
7
Treace Medical Concepts, Inc.
Reconciliation of GAAP Net Loss to Adjusted Net Loss
(in thousands, except share and per share amounts)
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Net loss |
|
$ |
(17,521 |
) |
|
$ |
(12,133 |
) |
|
$ |
(43,246 |
) |
|
$ |
(38,403 |
) |
Adjustment: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Debt extinguishment loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,483 |
|
Adjusted net loss |
|
$ |
(17,521 |
) |
|
$ |
(12,133 |
) |
|
$ |
(43,246 |
) |
|
$ |
(33,920 |
) |
Per share |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
(0.28 |
) |
|
|
(0.22 |
) |
|
|
(0.71 |
) |
|
|
(0.70 |
) |
Adjustment: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Debt extinguishment loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
0.08 |
|
Adjusted net loss |
|
$ |
(0.28 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.71 |
) |
|
$ |
(0.62 |
) |
Weighted average common shares outstanding per share attributable to common stockholders, basic and diluted |
|
|
61,562,494 |
|
|
|
55,429,211 |
|
|
|
60,566,655 |
|
|
|
55,190,587 |
|
Treace Medical Concepts, Inc.
Reconciliation of GAAP Net Loss to EBITDA & Adjusted EBITDA
(in thousands)
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
||||
Net loss |
$ |
(17,521 |
) |
|
$ |
(12,133 |
) |
|
$ |
(43,246 |
) |
|
$ |
(38,403 |
) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
(1,570 |
) |
|
|
(420 |
) |
|
|
(5,017 |
) |
|
|
(560 |
) |
Interest expense |
|
1,296 |
|
|
|
1,190 |
|
|
|
3,863 |
|
|
|
3,087 |
|
Taxes |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Depreciation & Amortization |
|
1,564 |
|
|
|
459 |
|
|
|
3,583 |
|
|
|
1,216 |
|
EBITDA |
$ |
(16,231 |
) |
|
$ |
(10,904 |
) |
|
$ |
(40,817 |
) |
|
$ |
(34,660 |
) |
Share-based compensation expense |
|
5,192 |
|
|
|
2,269 |
|
|
|
11,480 |
|
|
|
5,641 |
|
Acquisition-related costs |
|
1,802 |
|
|
|
— |
|
|
|
2,322 |
|
|
|
— |
|
Debt extinguishment loss |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,483 |
|
Adjusted EBITDA |
$ |
(9,237 |
) |
|
$ |
(8,635 |
) |
|
$ |
(27,015 |
) |
|
$ |
(24,536 |
) |
8